Stevanato's revenue for 2024 hit €1.1 billion, exceeding what analysts had predicted. This increase was mainly due to their Biopharmaceutical and Diagnostic Solutions, even though they faced difficulties with inventory. They are investing in expanding their facilities in Latina and Fishers to keep up with growing product demand, and they anticipate a large rise in sales.
Stevanato Group S.p.A. (NYSE:STVN) will hold its Q4 2024 earnings conference call on March 6, 2025, at 8:30 AM ET. The company representatives include Lisa Miles, Franco Stevanato, and Marco Dal Lago. Various analysts from different financial institutions will also participate in the call.
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a top global supplier of drug containment and delivery solutions for the pharmaceutical, biotechnology, and life sciences sectors, has announced its participation in the CJS Securities 25th Annual “New Ideas for the New Year” Investor Conference. This event will take place on Tuesday, January 14, 2025, at 8:00 a.m. ET. A live webcast of the event will be accessible on the Company's website at www.stevanatogroup.com in the "Investors" section.
In the third quarter of 2024, sales were higher than expected, but adjusted EBITDA and EPS did not meet forecasts because of lower usage and increased costs in the Engineering division. Even with these short-term challenges, we anticipate better margins in the future due to valuable solutions and the opening of new facilities. Overall, we believe in long-term growth and have decided to keep our buy rating.
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a top global supplier of drug containment and delivery solutions for the pharmaceutical, biotechnology, and life sciences sectors, has announced its participation in three upcoming investor conferences. The company will take part in a fireside chat at the UBS Global Healthcare Conference in Rancho Palos Verdes, California, on Tuesday, November 12, 2024, at 11:00 a.m. (PT). Additionally, the company will also make a presentation at another event.
Stevanato Group S.p.A. (NYSE:STVN) will hold its Q3 2024 earnings conference call on November 5, 2024, at 8:30 AM ET. The call will feature company representatives including Lisa Miles, Franco Stevanato, and Marco Dal Lago. Various analysts from different financial firms will also participate in the call.
Stevanato Group (STVN) reported quarterly earnings of $0.13 per share, matching the Zacks Consensus Estimate. This is a decrease from earnings of $0.16 per share from the same period last year.
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a top global provider of solutions for drug containment, delivery, and diagnostics in the pharmaceutical, biotechnology, and life sciences sectors, has announced that it will release its financial results for the third quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m. (ET). The company will also hold a conference call and webcast at 8:30 a.m. (ET) on the same day to discuss the results.
NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.
NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.